These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 22294324)
1. Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. Quesne JL; Jones J; Warren J; Dawson SJ; Ali HR; Bardwell H; Blows F; Pharoah P; Caldas C J Pathol; 2012 Jul; 227(3):306-14. PubMed ID: 22294324 [TBL] [Abstract][Full Text] [Related]
2. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer. Peurala H; Greco D; Heikkinen T; Kaur S; Bartkova J; Jamshidi M; Aittomäki K; Heikkilä P; Bartek J; Blomqvist C; Bützow R; Nevanlinna H PLoS One; 2011; 6(11):e26122. PubMed ID: 22102859 [TBL] [Abstract][Full Text] [Related]
3. Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. Shubbar E; Kovács A; Hajizadeh S; Parris TZ; Nemes S; Gunnarsdóttir K; Einbeigi Z; Karlsson P; Helou K BMC Cancer; 2013 Jan; 13():1. PubMed ID: 23282137 [TBL] [Abstract][Full Text] [Related]
4. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma. Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477 [TBL] [Abstract][Full Text] [Related]
6. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525 [TBL] [Abstract][Full Text] [Related]
7. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer. Luhtala S; Staff S; Tanner M; Isola J Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187 [TBL] [Abstract][Full Text] [Related]
8. Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis. Kapodistrias N; Mavridis K; Batistatou A; Gogou P; Karavasilis V; Sainis I; Briasoulis E; Scorilas A Oncotarget; 2017 Jan; 8(4):6896-6913. PubMed ID: 28036291 [TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of PDL1 expression in breast cancer. Sabatier R; Finetti P; Mamessier E; Adelaide J; Chaffanet M; Ali HR; Viens P; Caldas C; Birnbaum D; Bertucci F Oncotarget; 2015 Mar; 6(7):5449-64. PubMed ID: 25669979 [TBL] [Abstract][Full Text] [Related]
10. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer. Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268 [TBL] [Abstract][Full Text] [Related]
11. Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor. Minemura H; Takagi K; Miki Y; Shibahara Y; Nakagawa S; Ebata A; Watanabe M; Ishida T; Sasano H; Suzuki T Cancer Sci; 2015 Nov; 106(11):1642-50. PubMed ID: 26331797 [TBL] [Abstract][Full Text] [Related]
12. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688 [TBL] [Abstract][Full Text] [Related]
13. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy. Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Markers and Histologic Subtypes in Patients with Meningeal Carcinomatosis in Breast Cancer. Alnajar H; Rosen L; Javidiparsijani S; Al-Ghamdi Y; Gattuso P Acta Cytol; 2017; 61(2):140-144. PubMed ID: 28231581 [TBL] [Abstract][Full Text] [Related]
16. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571 [TBL] [Abstract][Full Text] [Related]
17. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions. Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376 [TBL] [Abstract][Full Text] [Related]
18. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Chen JQ; Litton J; Xiao L; Zhang HZ; Warneke CL; Wu Y; Shen X; Wu S; Sahin A; Katz R; Bondy M; Hortobagyi G; Berinstein NL; Murray JL; Radvanyi L Horm Cancer; 2010 Feb; 1(1):21-33. PubMed ID: 21761348 [TBL] [Abstract][Full Text] [Related]
19. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study. Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365 [TBL] [Abstract][Full Text] [Related]
20. ESPL1 is a candidate oncogene of luminal B breast cancers. Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]